Innovative vaccines for a healthier world

We want to transform healthcare by developing novel vaccines that are life-saving and improving quality of life around the world.

Interview with CEO Bent Frandsen

Explore ExpreS2ion Biotechnologies, an innovator within biotechnology.
In a detailed interview, CEO Bent Frandsen outlines our progress in developing innovative vaccines for a healthier world.
Uncover the substantial impact of our pioneering work and the compelling reasons to invest.
Engage with us as we lead in transformative solutions through the advanced capabilities of ExpreS2ion Biotechnologies.
 

Next Event

Latest News

ExpreS2ion to present in investor and R&D events in March

Hørsholm, Denmark, 29 February 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events during March.

Read more

ExpreS2ion’s Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic’s Clinical Phase III Study for the COVID-19 Vaccine

Hørsholm, Denmark, 21 February 2024 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") today announces that AdaptVac ApS (“AdaptVac”) has received 10 million EUR as a result of Bavarian Nordic having completed the clinical Phase III study of the COVID-19 vaccine ABNCoV2. The board of AdaptVac, in line with authority granted through AdaptVac’s…

Read more

ExpreS2ion announces financial results for the fourth quarter and full-year 2023

Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more